Breakthrough in EGFR-Mutated NSCLC: Rybrevant Plus Lazcluze Extends Overall Survival

The bispecific antibody Rybrevant plus Lazcluze significantly extended overall survival in patients with locally advanced or metastatic non-small cell lung cancer with certain epidermal growth factor receptor mutations, according to new top-line results from the phase 3 MARIPOSA study.